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Abstract
Background: K-RAS wild type colorectal tumors show an improved response rate to anti-EGFR
monoclonal antibodies. Nevertheless 70% to 40% of these patients still does not seem to benefit
from this therapeutic approach. FISH EGFR GCN has been previously demonstrated to correlate
with clinical outcome of colorectal cancer treated with anti-EGFR monoclonal antibodies. CISH
also seemed able to provide accurate EGFR GCN information with the advantage of a simpler and
reproducible technique involving immunohistochemistry and light microscopy. Based on these
findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical
outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab.
Methods:  Patients with advanced K-RAS wild-type, colorectal cancer receiving irinotecan-
cetuximab after failure of irinotecan-based chemotherapy were eligible.
A cut-off value for EGFR GCN of 2.6 and 2.12 for FISH and CISH respectively was derived from
ROC curve analysis.
Results: Forty-four patients were available for analysis. We observed a partial remission in 9 (60%)
and 2 (9%) cases with a FISH EGFR GCN ≥ 2.6 and < 2.6 respectively (p = 0.002) and in 10 (36%)
and 1 (6%) cases with a CISH EGFR GCN ≥ 2.12 and < 2.12 respectively (p = 0.03). Median TTP
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was 7.7 and 6.4 months in patients showing increased FISH and CISH EGFR GCN whereas it was
2.9 and 3.1 months in those with low FISH and CISH EGFR GCN (p = 0.04 and 0.02 respectively).
Conclusion: FISH and CISH EGFR GCN may both represent effective tools for a further patients
selection in K-RAS wild-type colorectal cancer treated with cetuximab.
Background
The expanding role of anti-EGFR therapeutic modalities
in colorectal cancer along with the growing number of
cases potentially requiring such a treatment approach
made the need for a correct and reliable identification of
responding tumors even more relevant [1-7].
Since its early introduction, the use of K-RAS mutational
status as a predictive factor for anti-EGFR targeted mono-
clonal antibodies seemed to possess the necessary poten-
tial for a full translation into clinical practice of the true
concept of targeted therapy in this setting. Research data
from retrospective series have in fact repeatedly demon-
strated that a K-RAS mutant status was strictly correlated
to clinical resistance to EGFR-targeted monoclonal anti-
bodies [7-12]. Consequently the evaluation of K-RAS in
colorectal tumors promised to allow a more accurate
treatment selection with a consistent and highly desired
reduction of unnecessary toxic effects and economic costs.
However if on the one hand we are now able to exclude
from anti-EGFR treatment with monoclonal antibodies
those patients with putative refractory colorectal tumors
(i.e. those harboring a K-RAS mutation), on the other
hand we are still incapable to accurately select responding
patients among those without K-RAS mutations. Pub-
lished data clearly suggest that a non negligible propor-
tion of patients, ranging from 70% to 40% in different
series, does not seem to benefit from the use of anti-EGFR
targeted antibodies although in the absence of a mutation
of the K-RAS gene (i.e. K-RAS wild-type) [7-12].
Along with other biological determinants (such as B-RAF
mutation analysis) [12] EGFR gene copy number (GCN)
as determined by fluorescence in situ hybridization
(FISH) analysis seemed to correlate with response to anti-
EGFR monoclonal antibodies in an initial study by
Moroni et al [13]. These findings were subsequently con-
firmed in a further retrospective analysis from the same
group of investigators but in a larger and more homoge-
neous series [14]. A more recent analysis investigating
colorectal cancer patients receiving cetuximab showed
once again that cases with high EGFR GCN have an
increased likelihood to respond to therapy [15]. Taken
together data from all these studies suggest a strong role
for EGFR GCN in predicting the activity of EGFR targeted
monoclonal antibodies in colorectal cancer patients. Nev-
ertheless FISH technique is expensive, time consuming,
and requires a special protocol, materials and fluorescent
microscopy. In contrast chromogenic in situ hybridiza-
tion (CISH), which utilizes a peroxidase reaction to detect
the locus of interest, can be performed in the clinical
immunohistochemistry laboratory and interpreted by
standard light microscopy [16]. The reliability of CISH in
detecting HER-2 gene amplification has been previously
proved in breast tumors [17,18]. Furthermore this analy-
sis technique seemed more recently able to provide EGFR
GCN information as accurate as that supplied by FISH in
non small cell lung cancer [19]. This technique for deter-
mination of EGFR GCN has been validated in colorectal
tumors as well [20]. We then decided to investigate the
correlation between both FISH and CISH EGFR GCN and
clinical outcome in terms of response rate and time to
progression (TTP) in irinotecan-refractory K-RAS wild-
type colorectal cancer patients treated with irinotecan-
cetuximab. This was done in order to identify a possible
simplified molecular determinant of response in this
group of patients.
Methods
Patients selection
Patients with histologically proven EGFR-positive, K-RAS
wild-type, metastatic, colorectal cancer previously treated
with an irinotecan-based chemotherapy regimen and
receiving a combination of cetuximab and irinotecan were
eligible for our retrospective analysis. To be eligible
patients must also have received the irinotecan-based
chemotherapy regimen for at least 6 weeks and must have
presented progression of disease during receipt of this reg-
imen or within three months thereafter. All patients
received cetuximab at an initial dose of 400 mg per square
meter followed by weekly infusions of 250 mg per square
meter. Irinotecan was administered at a dose of 180 mg
per square meter every 2 weeks either alone or in combi-
nation with 5 fluorouracil and leucovorin. Tumor
response was evaluated every 8 weeks by clinicians' assess-
ment and according to the Response Evaluation Criteria
in Solid Tumors (RECIST). This study was approved by the
institutional ethics committee. Informed consent was
obtained from participants of the study.
K-RAS mutational analysis
Formalin-fixed and paraffin-included tumor samples were
analyzed for KRAS exon 2 mutations, located within the
codon 12 and 13 (Gly12Asp, Gly12Ala, Gly12Val,
Gly12Ser, Gly12Arg, Gly12Cys and Gly13 Asp).BMC Cancer 2009, 9:303 http://www.biomedcentral.com/1471-2407/9/303
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For each tumor sample the neoplastic area was selected
and DNA was extracted using the DNA extraction kit from
QIAGEN (QIAamp® DNA Mini and Blood Mini). The
DNA extracted was PCR amplified using the following
sense and antisense primer: 5'-AAGGCCTGCTGAAAAT-
GACTG-3' and 5'-CAAAGAATGGTCCTGCACCAG-3'.
After the purification using QIAquick® PCR Purification
kit, the PCR products were direct sequenced with Big Dye
V1.1 Terminator Kit (Applied Biosystems, Foster City, CA,
USA) and an ABI Prism 3100 DNA sequencer (Applied
Biosystems).
FISH analysis
Analysis of EGFR amplification was performed using the
standard dual-colour EGFR Spectrum Orange™/CEP7®
Spectrum Green™ probe (Visys, Downers Grove, IL USA).
In brief, paraffin sections were deparaffinizzed, dehy-
drated in ethanol and air-dried. After treatment in 0,05%
pepsin/0,1 N HCL for 45 min at 37°C, the sample were
aged in 0,1% NP-40/2 × SSC (Standard Saline Citrate
solution) for 10 min at 37°C and DNA was denatured by
treatment in 70% formamide/2 × SSC for 4 min at 85°C.
A measure of 5 μl of the probe solution was then placed
on a glass slide with a coverslip. The sample slides were
hybridized overnight at 37°C and washed in 0,4 × SSC/
0,3% NP-40 at 73°C for 2 min. Nuclei were counter-
stained with 4',6-diamino-2-phenylindole dihydrochlo-
ride and p-phenylenediamine in phosphate-buffered
saline and glycerol (DAPI II) (Vysis). Each FISH assay
included normal breast tissue sections, as negative con-
trol, and sections of breast cancer previously confirmed to
have amplification of EGFR as positive control.
FISH analysis was performed using a fluorescence micro-
scope (Nikon Optphot-2 and Quips Genetic Workstation)
equipped with the Tripple Bandpass Filter set (Vysis) for
DAPI II, SpectrumOrange and SpectrumGreen. Filter was
specifically set to SpectrumOrange and SpectrumGreen.
Only individual and well delineated cells were scored;
overlapping cells were excluded from the analysis. At least
60 cells were scored for each case or control sample.
Each tumor was assessed by the average (GCN), the max-
imum numbers of the copies of EGFR gene per cell, the
average EGFR/chromosome 7 copy number (CEP7) ratio
and ploidy.
Amplification was defined as ratio of EGFR signals to
chromosome 7 centromere signals of 2 or more. Poly-
ploidy was defined as a mean of >2 chromosome 7 sig-
nals, per cell. The percentage of the cells showing
polyploidy and EGFR amplification (% CEP7 >2; %
EGFR/CEP 7 ≥ 2) was estimated for each tumor.
FISH results were evaluated independently by two pathol-
ogist (IB and AM) who were blinded about clinical out-
come.
CISH analysis
Chromogenic in situ hybridization for the EGFR gene was
performed according to manufacturer's instructions
(Zymed Laboratories Inc., South San Francisco, Califor-
nia, USA).
Briefly the sections of the formalin-fixed and paraffin-
embedded tissue were incubated at 55°C overnight. The
slides were then deparaffinizzed in xylene and graded eth-
anols. Pre-treatment heating was carried out in the pre-
treatment buffer (Zymed Laboratories Inc.) at 96°C for 15
min.
The tissue was digested with pepsin for 10 min at room
temperature, subsequently it was washed with deionised
water, dehydrated with graded ethanol and air dried.
After application of Zymed Spot-Light®  oligoxigenin
labeled EGFR probe (Zymed Laboratories Inc.), the slides
were coverslipped and edges sealed with rubber cement.
The slides were heated at 92°C for 5 min followed by
overnight incubation at 37°C using moisturized chamber.
Post hybridization wash was performed the next day and
followed by immunodetection using the CISH™ polymer-
detection Kit (Zymed Laboratories Inc.).
The CISH signals were seen as dark brown dots and
counted in at last 100 nuclei with a light microscopy using
a × 40 objective. Only individual and well delineated cells
were scored; while overlapping cells were excluded from
the analysis. Also the average EGFR gene copies per
nucleus for each tissue sections was calculated (EGFR
GCN).
According to previous reports [16-20], a gene copy
number of six o more in the nucleus in more than 50% of
tumor cells was taken to indicate amplification of the
EGFR gene. Cases with three to five gene copies were con-
sidered aneuploid.
CISH results were evaluated independently by two pathol-
ogist (IB and AM) who were blinded about clinical out-
come.
Statistical Analysis
Receiver operating characteristics (ROC) curve analysis
was performed to determine a cut off value for FISH and
CISH EGFR GCN continuous variables.BMC Cancer 2009, 9:303 http://www.biomedcentral.com/1471-2407/9/303
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The association between EGFR FISH and CISH GCN and
response rate was estimated by Fisher's exact test.
Survival distribution was estimated by the Kaplan-Meier
method. Significant differences in probability of relapsing
between the strata were evaluated by log-rank test.
For statistical analysis overall survival (OS) and time to
progression (TTP) were defined respectively as the interval
between the start of cetuximab and irinotecan therapy to
death or last follow-up visit and as the interval between
the start of cetuximab and irinotecan therapy to clinical
progression or death or last follow up visit if not pro-
gressed.
Statistical significance was set at p < 0.05 for each analysis.
Results
Forty-four patients were eligible for our analysis, 23 males
(52%%) and 21 females (48%), median age at diagnosis
was 66 (range 39–78). Fourteen patients (32%) received
cetuximab-irinotecan therapy as a second-line treatment,
the remaining 30 cases (68%) were treated with cetuxi-
mab-irinotecan after failure of at least 2 previous lines of
chemotherapy. Overall we observed a partial response in
11 patients (25%) and progressive disease in 21 cases
(48%). Twelve patients (27%) showed a tumor stabiliza-
tion, while no complete remissions were obtained.
Median time to progression for the whole patients popu-
lation was 3.6 months and median overall survival was
10.6 months (Table 1). All patients but 3 (9%) received
cetuximab in combination with irinotecan alone.
FISH and CISH analysis for EGFR GCN was performed in
primary tumors in all cases. In our series we observed only
one case of EGFR amplification as defined by FISH (3%)
and 1 case as defined by CISH (2%). FISH EGFR poly-
ploidy was detected in 18 cases (48%). No correlation
between FISH EGFR polyploidy, response rate, time to
progression and overall survival was evident. The cut-off
point with the highest sensitivity and specificity for esti-
mating FISH EGFR GCN was set at 2.6 after ROC curve
analysis (Figure 1).
FISH analysis was possible in 37 cases.
Table 1: Patients characteristics and global results for FISH/CISH EGFR GCN analysis and clinical outcome.
Total Population EGFR FISH GCN
≥ 2.6
EGFR FISH GCN
< 2.6
P EGFR CISH GCN
= 2.12
EGFR CISH GCN
< 2.12
p
Number (%) 44 15 (40) 22 (60) 28 (64) 16 (36)
Sex (%)
Male 23 (52) 10 (67) 13 (60) 15 (53) 9 (56)
Female 21 (48) 5 (33) 9 (40) 13 (47) 7 (44)
Median age 
(range)
66 (39–78) 66 (39–78) 66 (39–78) 65 (39–78) 66 (40–78)
Previous lines of 
Chemotherapy 
(%)
1 14 (32) 5 (33) 8 (36) 8 (29) 6 (37)
> 2 30 (68) 10 (67) 14 (64) 20 (71) 10 (63)
Response Rate 
(%)
Complete 
Remission
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Partial Remission 11 (25) 9 (60) 2 (9) 0.002 10 (36) 1 (6) 0.03
Stable Disease 12 (27) 5 (33) 8 (32) 10 (36) 2 (13)
Progressive Disease 21 (48) 1 (7) 13 (59) 0.001 8 (30) 13 (81) 0.01
Not assessable 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Survival (Months)
Time to Progression 3.6 7.7 2.9 0.04 6.4 3.1 0.02
Overall Survival 10.6 16 9.5 10.6 10.3
Only statistically significant p values have been included.BMC Cancer 2009, 9:303 http://www.biomedcentral.com/1471-2407/9/303
Page 5 of 8
(page number not for citation purposes)
FISH EGFR GCN ≥ 2.6 was present in 15 (40%) colorectal
tumors, whereas it was < 2.6 in the remaining 22 (60%)
patients (table 1).
All major clinical characteristics resulted comparable
among the two groups of patients (FISH EGFR GCN ≥ 2.6
and < 2.6). In particular no differences were noticed for
sex, age at diagnosis and previous lines of chemotherapy
(Table 1). On the contrary in patients showing a FISH
EGFR GCN ≥ 2.6 we observed 9 partial remissions (60%)
whereas 2 partial remission (9%) was observed in those
showing a FISH EGFR GCN < 2.6 (p = 0.02). Accordingly
FISH EGFR GCN ≥ 2.6 was also associated with a lower
progression rate compared to FISH EGFR GCN < 2.6. In
fact progressive disease was observed in 1 (7%) and 13
(59%) cases respectively (p = 0.001) (Table 1). Median
time to progression was 7.7 months in patients showing
FISH EGFR GCN ≥ 2.6 and 2.9 months in those showing
FISH EGFR GCN < 2.6 (p = 0.04) (Figure 2). No statisti-
cally significant difference was noticed in median overall
survival (Figure 3).
CISH analysis was possible in 44 cases.
The cut-off point with the highest sensitivity and specifi-
city for estimating CISH EGFR GCN was set at 2.12 after
ROC curve analysis (Figure 4).
EGFR GCN ≥ 2.12 was present in 28 (64%) colorectal
tumors, whereas it was < 2.12 in the remaining 16 (36%)
patients.
All major clinical characteristics resulted comparable
among the two groups of patients (EGFR GCN ≥ 2.12 and
< 2.12). In particular no differences were noticed for sex,
age at diagnosis and previous lines of chemotherapy
(Table 1). On the contrary in patients showing a CISH
EGFR GCN ≥ 2.12 we observed 10 partial remissions
(36%) whereas 1 partial remission (6%) was observed in
those showing a CISH EGFR GCN < 2.12 (p = 0.03).
Accordingly CISH EGFR GCN ≥ 2.12 was also associated
Receiver operating characteristics (ROC) analysis based on  mean FISH EGFR gene copy number with response to cetux- imab therapy as end point Figure 1
Receiver operating characteristics (ROC) analysis 
based on mean FISH EGFR gene copy number with 
response to cetuximab therapy as end point. In this 
model sensitivity was 96.3% (95% CI 81 – 99.4) and specifi-
city was 90% (95% CI 55.5–98.3). AUC was 0.95, p = 0.0003.
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with a lower progression rate compared to CISH EGFR
GCN < 2.12. In fact progressive disease was observed in 8
(30%) and 13 (72%) cases respectively (p = 0.01) (Table
1). Median time to progression was 6.4 months in
patients showing CISH EGFR GCN ≥ 2.12 and 3.1 in those
showing CISH EGFR GCN < 2.12 (p = 0.02) (Figure 5). No
statistically significant difference was noticed in median
overall survival (Figure 6). In all responding patients eval-
uation of both EGFR FISH and CISH GCN was possible.
An evident correspondence between results was observed
in all but one case (Table 2).
Discussion
Biologically targeted agents for the treatment of colorectal
cancer held along with an improved therapeutic level, the
promise for a more accurate selection of patients candi-
date for such a treatment. The use of the anti-EGFR mon-
oclonal antibodies in the clinical practice seemed to
confirm the activity profile previously suggested [1-3].
Unfortunately the introduction of anti-EGFR monoclonal
antibodies made also rapidly clear to the clinicians that a
reliable predictive factor for outcome was, in fact, lacking
[3-7]. The introduction of K-RAS mutational status analy-
sis allowed a reliable selection of resistant patients (i.e.
those with mutated K-RAS). However not all K-RAS wild-
type cases were also responders to anti-EGFR monoclonal
antibodies. This observation made the need for further
Receiver operating characteristics (ROC) analysis based on  mean CISH EGFR gene copy number with response to  cetuximab therapy as end point Figure 4
Receiver operating characteristics (ROC) analysis 
based on mean CISH EGFR gene copy number with 
response to cetuximab therapy as end point. In this 
model sensitivity was 51.5% (95% CI 33.6–69.2) and specifi-
city was 100% (95% CI 69–100). AUC was 0.77, p = 0.002.
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Table 2: Correlation results for EGFR FISH and CISH GCN in 
patients responding to treatment
Case Number EGFR FISH GCN ≥ 2.6 EGFR CISH GCN ≥ 2.12
3 2.6 2.12
10 2.9 2.13
13 1.48 2.09
19 2.6 2.78
20 3.03 4.03
22 2.7 3.18
26 2.6 2.43
29 2.83 5.15
31 3.85 2.96
35 1.92 2.63
37 2.9 2.6
In all responding patients evaluation of both EGFR FISH and CISH 
GCN was possible and an evident correspondence between results is 
observable in all but one case.BMC Cancer 2009, 9:303 http://www.biomedcentral.com/1471-2407/9/303
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selection even more crucial [7-12]. EGFR gene copy
number as determined by FISH analysis seemed to corre-
late with response to anti-EGFR monoclonal antibodies in
previous studies [13-15]. Taken together data from all
these studies suggest a strong role for FISH EGFR GCN in
predicting the activity of EGFR targeted monoclonal anti-
bodies. Furthermore a previous report also suggested that
EGFR GCN analysis may help identifying responding
patients among wild-type colorectal cancer patients [15].
In the present analysis FISH EGFR GCN ≥ 2.6 correlated
with improved response rate and time to progression,
confirming its prominent role in predicting clinical out-
come to cetuximab therapy even among K-RAS wild-type
colorectal tumors and globally suggesting the possibility
to further identify responding patients with the use of
combined K-RAS mutation and FISH EGFR GCN analyses.
Chromogenic in situ hybridization (CISH), may represent
a further improvement in this setting. Unlike breast
tumors, colorectal cancer cells often show an overlapping
growth pattern in the examination specimen making FISH
analysis less reproducible and harder to interpret. The
CISH technique seems able to overcame this potentially
confounding factor as it offers the opportunity to mor-
phologically identify overlapping tumor cells, which can
be consequently excluded from the analysis. In our series
CISH EGFR GCN was also able to identify colorectal can-
cer patients more likely to respond to irinotecan-cetuxi-
mab therapy. In fact patients showing CISH EGFR GCN ≥
2.12 obtained an interesting 37% response rate whereas
response rate was 0% in those with a CISH EGFR GCN <
2.12 (p = 0.0007). Progression rate was also influenced by
CISH EGFR GCN (30% vs. 72% in EGFR GCN ≥ or < 2.12
respectively). Accordingly Median TTP was 6.4 months in
patients showing increased CISH EGFR GCN whereas it
was 3.1 months in those with low CISH EGFR GCN (p =
0.01). Combined results for EGFR FISH and CISH GCN
suggested that either FISH or CISH may be used for deter-
mination of EGFR GCN substantially depending on each
laboratory expertise.
Multiple predictive factors to anti-EGFR monoclonal anti-
bodies treatment have been analyzed since this new class
of anti-cancer agents have been introduced in the clinical
practice and after the role of K-RAS was clarified in this set-
ting. Among the others a particular role may be attributed
to molecular factors that are key regulators of EGFR down-
stream pathways not influenceable by EGFR upstream
directed therapeutic agents (i.e. cetuximab and panitumu-
mab). Tumor NF-kB and B-RAF mutation status are inter-
esting examples of such molecular factors [12,21].
However none of these factors seemed strong enough to
translate into clinical practice, mostly because these
response determinants singularly taken do not account of
all responding (or resistant) patients. The present lack of
prospective studies is another evident obstacle to their full
introduction into practice. We believe that only a prospec-
tive analysis comprehensive of those biological markers
suspected to be implicated in response/resistance to EGFR
directed therapeutic agents could give researchers and cli-
nicians a full picture of the mechanisms underlying the
efficacy of such agents.
Conclusion
Globally our findings indicate that EGFR GCN as deter-
mined either by FISH or CISH may represent a valuable
asset in the common effort of better defining, among the
group of metastatic K-RAS colorectal cancer patients
treated with anti-EGFR antibodies, those more likely to
benefit from such a treatment strategy. This approach if
further explored seem to possess the required potential to
improve the therapeutic effect of this class of molecules in
potentially responding patients avoiding unnecessary side
effects in resistant cases.
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